A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients — Stella

Home/Vaginitis/

View on ClinicalTrials.gov

Recruiting

Back to Vaginitis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

251 Yaojiayuan Road, Chaoyang District, Beijing, Beijing, Beijing Municipality

Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Cisen Pharmaceutical CO., LTD.

Enrollment target

~108 participants

Started

January 2025

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 64 Years

Sex

Female only

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.